Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Earnings Preview: Agenus (AGEN) Q4 Earnings Expected to Decline
01:38pm, Monday, 08'th Mar 2021
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strong Buy: Agenus' iNKT Cell-Therapy Extubated 3 Of First 4 Severe COVID-19 Patients In P1 Trial
12:02pm, Wednesday, 10'th Feb 2021
Preliminary Phase 1 trial results show three of four intubated COVID-19 patients were discharged after treatment via AGEN's new iNKT cell-therapy. Incredibly, two were extubated within 24 hours of dos
Andy Hurley Named Agenus Chief Commercial Officer
05:06pm, Tuesday, 09'th Feb 2021
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus Announces Agenus Insights - Virtual R&D Miniseries
11:00am, Tuesday, 09'th Feb 2021
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus Announces New Responses for AGEN1181
08:45am, Tuesday, 09'th Feb 2021
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
08:30am, Thursday, 04'th Feb 2021
LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus to Participate in B. Riley Securities' Oncology Investor Conference
12:09pm, Tuesday, 19'th Jan 2021
LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
XOMA: A Royalty Aggregator To Watch
04:43pm, Monday, 04'th Jan 2021
XOMA: A Royalty Aggregator To Watch
Completion of Balstilimab BLA Filing Extended To 1H2021
07:45am, Thursday, 03'rd Dec 2020
Agenus to fulfill FDA feedback for six-month follow-up on late responders Agenus to fulfill FDA feedback for six-month follow-up on late responders
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
01:28pm, Wednesday, 25'th Nov 2020
LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference
07:04pm, Monday, 16'th Nov 2020
LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus: A Buy With iNKT Therapy, MK-4830 Milestone
11:09pm, Friday, 13'th Nov 2020
Agenus is nearing multiple upward inflection points. iNKT therapy trial started, showing immunotherapy leadership.
Agenus and Dr. Steven O'Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
02:43pm, Friday, 13'th Nov 2020
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccine
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2
08:45am, Tuesday, 10'th Nov 2020
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
08:15am, Monday, 09'th Nov 2020
LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccine
